Copy Link Print Information

2’3’-c-di-AM(PS)2 (Rp,Rp)

(Synonyms: ADU-S100; MIW815; ML RR-S2 CDA)
90 Cited Publications
Customer Review

Based on 90 publication(s) in Google Scholar

2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity.

For research use only. We do not sell to patients.

  • Purity: 99.59%
  • CAS No.: 1638241-89-0
  • Formula: C20H24N10O10P2S2
  • Molecular Weight:690.54
  • Storage:

    -20°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • 2’3’-c-di-AM(PS)2 (Rp,Rp) Chemical Structure
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • 2’3’-c-di-AM(PS)2 (Rp,Rp) Chemical Structure
    2’3’-c-di-AM(PS)2 (Rp,Rp) Chemical Structure
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
  • Experimental Validation Results for 2’3’-c-di-AM(PS)2 (Rp,Rp)
CAS No.: 1638241-89-0
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) 2’3’-c-di-AM(PS)2 (Rp,Rp)

More
Customer Validation & Images
Cell Proliferation/Viability AssayIn Vivo Efficacy StudyWBIHCFlow CytometryRT-PCR
  • WB
  • Flow Cytometry
  • IHC
  • RT-PCR
  • In Vivo Efficacy Study
  • IHC
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • RT-PCR
Keywords
100 mg
Get Quote In-stock
Please select quantity
Price: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 2’3’-c-di-AM(PS)2 (Rp,Rp) Chemical Structure
    2’3’-c-di-AM(PS)2 (Rp,Rp) Chemical Structure
    1/16
  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]

    Customer Validation
     2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) (10 μM) was added to the culture of KPC cells or endothelial cells (HUVEC) for indicated time, and the activation of STING signaling was analyzed by IRF3 Ser385 phosphorylation. The quantification of phosphorylated IRF3 was normalized by total IRF3. β-actin was used as a loading control.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]

    Customer Validation
     Leukocytes were isolated from peripheral blood or the peritoneum of normal mice and incubated in vitro with 7.2  μg/mL STING agonist 2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) for 2 h at 37 °C. Phosphorylation of IRF3 in leukocyte subsets (CD11b+ myeloid cells, CD3+ cells, CD19+ cells, and NK1.1+ cells) was detected by α-phospho-IRF3 Ser385 antibody staining. Cells were permeabilized using eBioscience™ Transcription Factor Staining Buffer Set before staining. The percent fraction of phospho-IRF3+ cells in each subset of blood or peritoneal leukocytes was determined by flow cytometry.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1766-1780. [Abstract]

    Customer Validation
     STING agonist 2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) (2 μg intratumoral) and/or anti-LTβR agonistic antibody (100 μg, intraperitoneal (i.p.)) were administered to mice bearing subcutaneous KPC tumors as monotherapy or in combination as indicated. Immunohistochemistry of B cells (CD19, brown) and HEVs (MECA-79, magenta) shows numerous TLS induced by combination therapy (day 14). Scale bars, 1 mm (low magnification) and 100 μm (high magnification).

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(16):e2414110. [Abstract]

    Customer Validation
     The relative mRNA expression of Ifnβ1 in 4T1 cells, MC38 cells and B16F10 cells after treatment with TACTIC, CS or ADU‐S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt, 20 µg/mL; 24 h) (n = 3).

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Sep 22:S1525-0016(25)00761-0. [Abstract]

    Customer Validation
     Titration of the agonist ADU-S100 in B16-OVA tumor model. OVA mRNA, 10 μg; C1, 1.6 mg; ADU-S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt): 10/20/40 μg. n=5 mice per group. The results indicated that the ADU-S100 dosage used (20 μg/mice) was likely optimal for the C1-mRNA+ADU-S100(nano) cancer vaccine.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Sep 22:S1525-0016(25)00761-0. [Abstract]

    Customer Validation
     Representative images of tumor-infiltrating CD8+ T cells by immunohistochemistry (left) and quantification of CD8+ T cells (right). Scale bars: 100 μm (upper) and 50 μm (lower). Tumor-infiltrating immune cell analysis by immunohistochemistry demonstrated that CD8+ T cells were enriched in tumors from Stingf/f Itgax-Cre– mice immunized with C1-OVA mRNA+ADU-S100(nano), but not in tumors from Stingf/f Itgax-Cre+ mice. The doses of mRNA vaccine per mouse in vivo were as follows: mRNA, 10 μg; C1, 1.6 mg; ADU-S100, 20 μg; c-di-AMP, 20 μg. C1-mRNA + ADU-S100(nano) was prepared by encapsulating ADU-S100 into the C1-mRNA nanovaccine during nanoparticle preparation.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     Cell viability assays of isogenic NTC, Trp53 KO, and Bak/Bax KO Eμ-Myc lymphoma cell lines treated with S63845 in combination with ADU-S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt, 2-10 μg/mL), MSA-2 (12-34 μM), or diABZI for 24 h.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     RT-qPCR for BH3-only and STING target genes in three independent isogenic NTC and Trp53 KO Em-Myc lymphoma cell lines treated with ADU-S100 (2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt, 10 μg/mL) for 24 h.Fold change is relative to the AH15A DMSO-treated NTC sample

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     Cell viability assays of Eμ-Myc lymphoma cell lines treated with ADU-S100 (HY-12885A; AH15A/560: 0.5 μg/mL; 47A: 5 μg/mL) and/or TPCA-1 (HY-10074) for 24 h. Error bars represent SD for three independent experiments. Diagram illustrates how TPCA-1 acts to inhibit NF-κB signaling.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1585-1596. [Abstract]

    Customer Validation
     Cell viability assays measuring 5-FU response in cGAS knockdown HCT116 cells stably expressing shRNA-resistant cGAS-S213D mutants or pretreated with 10 µM 2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100) for 6 hours.

  • 1/16

    2’3’-c-di-AM(PS)2 (Rp,Rp) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Mar 13;14(1):1390. [Abstract]

    Customer Validation
     ADU-S100 (10 μM; 48 h; labeled as STING) enhances type I interferon gene expression in human dendritic cells (DCs).

  • 2’3’-c-di-AM(PS)2 (Rp,Rp)